Midas Pharma

What Midas Pharma does

Midas Pharma GmbH is a privately held, family-owned pharmaceutical services company founded in 1988 and headquartered in Ingelheim, Germany. The company provides an integrated portfolio spanning the full pharmaceutical value chain — from raw materials and chemicals, through intermediates and active pharmaceutical ingredients (APIs), to finished dosage forms, medical devices, and platform technologies — alongside a parallel suite of services including contract development, contract manufacturing under GMP, supply chain management, regulatory affairs, quality/compliance (anchored by the proprietary Midas Audit Database), intellectual property services, and business development and licensing support. Its Midas Biopharma sub-brand and the 2025 merger with Biofidus extend the offering into biopharmaceutical CDMO, while the Gx Inbeneo® autoinjector platform and Hot Melt Extrusion platform technology represent proprietary device and formulation capabilities.

The company operates through 12 subsidiaries and affiliates across all major pharmaceutical markets (including Germany, France, China, and Turkey) and employs approximately 366 people worldwide representing 24 nationalities, with 80% holding university degrees. Midas Pharma serves pharmaceutical manufacturers, biotechnology companies, and medical device developers as a B2B partner, monetizing through product sales, CDMO services, supply chain management, and licensing/royalty arrangements. Go-to-market is enterprise field sales supplemented by participation in major industry events (CPhI Worldwide, Bio International, CPhI China, Chemspec Europe), with quote-based pricing rather than disclosed list prices.

Midas Pharma maintains a portfolio of regulatory assets including CEP certifications for Propofol, Clofazimin, and a Sister-CEP for Doxazosinmesilat from EDQM, a US Drug Master File for Propofol, Qualifyze Gold status (2024), and the EcoVadis Gold Medal (2026, upgraded from Silver in 2025). It has been recognized with a Red Dot Award for the Gx Inbeneo® autoinjector and consecutive kununu Top Company employer designations (2025, 2026). Revenue, ARR, and ownership structure beyond family control are not publicly disclosed.

Name

Midas Pharma

Legal name

Midas Pharma GmbH

Website

https://midas-pharma.com

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

251–500 employees

Short description

Midas Pharma is a family-owned German pharmaceutical services company offering products, CDMO services, and supply chain solutions across the full pharma value chain — from chemicals and APIs to medical devices and licensing — to pharmaceutical manufacturers, biotechs, and medical device developers worldwide through 12 global affiliates.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Development & Manufacturing Services (CDMO)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO), Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

• Pharmaceutical services
• Contract development manufacturing
• Active pharmaceutical ingredients
• Pharmaceutical supply chain
• Drug substance manufacturing

Headquarters

HQ city

Ingelheim

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Product Sales: Sale of pharmaceutical chemicals, intermediates, drug substances (APIs), finished dosage forms, and medical devices to pharmaceutical manufacturers and biotech companies
2. Contract Development & Manufacturing Services: CDMO services including contract development of intermediates, drug substances, and finished drug products, as well as contract manufacturing services under GMP compliance
3. Supply Chain Management Services: Supply chain management, regulatory services, quality compliance services, and reference products sourcing for the pharmaceutical industry
4. Business Development & Licensing: In-licensing and out-licensing of pharmaceutical products, API and FDF technology transfer, supplier relationship management, and API/Intermediates representations

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Midas Pharma is a diversified pharmaceutical services and products company that supplies chemicals, intermediates, drug substances (APIs), finished dosage forms, and medical devices, and provides integrated contract development, contract manufacturing, supply chain management, quality/compliance, regulatory, and licensing services across the full pharmaceutical value chain for pharmaceutical manufacturers and biotech companies worldwide.

Product overview

Midas Pharma is a diversified pharmaceutical services company offering products and services across the full pharmaceutical value chain. The portfolio includes Chemicals (raw materials), Intermediates (including specialized categories for Biopharma and Pharma, plus Deuterated Substances), Drug Substances (APIs), Drug Products with BD & Licensing capabilities (Finished Dosage Forms and Consumer Healthcare Products), Medical Devices (including the Gx Inbeneo® Autoinjektor platform), and Platform Technologies (Hot Melt Extrusion). Services include Contract Development and Manufacturing, Quality/Safety/Compliance, Supply Chain Management, Intellectual Property Services, and Regulatory Support. The company operates through business development and partnering services, with a specialized Midas Biopharma division for integrated biotech solutions. The company is headquartered in Ingelheim, Germany with 12 offices worldwide serving as a partner for pharmaceutical companies requiring integrated end-to-end solutions from early-stage R&D to market launch.

Differentiator

Problem solved

Functional benefit

Brands

• Midas Biopharma: Partner along the biopharmaceutical value chain, offering integrated end-to-end solutions from early-stage R&D to market launch.
• Midas Chemicals
• Gx Inbeneo®

Products and services

• Chemicals Raw materials and chemicals supplied for industries such as pharmaceuticals, agriculture, and paper & pulp.
• Intermediates Chemical or biotechnological reaction products formed at defined stages during the manufacturing of an active ingredient or drug product, functioning as key building blocks within synthesis pathways for pharmaceutical manufacturers.
• Drug Substances (APIs) Active Pharmaceutical Ingredients (APIs) — the pharmacologically active components of medicinal products — manufactured in GMP-compliant processes for pharmaceutical companies.
• Drug Products / BD & Licensing Finished dosage forms plus business development and licensing services for drug products, including Finished Dosage Forms (tablets, capsules, solutions) and Consumer Healthcare (OTC) products.
• Medical Devices (Gx Inbeneo®) Medical devices including the Gx Inbeneo® autoinjector system that enables patients to self-administer medication safely and reliably by automating dose delivery, needle deployment and injection, plus the Gx Inbeneo® Platform Simulator for training and demonstration.
• Platform Technologies — Hot Melt Extrusion (HME) Hot Melt Extrusion process technology that combines active ingredients and excipients under heat and pressure into a homogeneous melt to produce solid dosage forms with enhanced drug properties or improved solubility.
• Contract Development Services Development services for intermediates, drug substances, and finished drug products including formulation development, process development, and analytical method development and validation.
• Contract Manufacturing Services GMP-compliant contract manufacturing of active substances and finished pharmaceutical products performed exclusively on behalf of pharmaceutical companies.
• Supply Chain Management Planning, coordination, and monitoring of supply chain processes related to packaging, storage, logistics, distribution, and inventory management to ensure timely product availability for pharmaceutical clients.
• Quality, Safety and Compliance Services Quality services, the Midas Audit Database, regulatory services, and pharmacovigilance services ensuring GMP/GDP compliance across the pharmaceutical value chain.
• Intellectual Property Services IP services including freedom-to-operate analysis, gap analysis, and intellectual property portfolio management for pharmaceutical clients.
• Reference Products Sourcing Sourcing of reference products (originator medicines) used to compare generics or biosimilars for pharmaceutical companies.
• Midas Biopharma Sub-brand offering integrated end-to-end biotech solutions — partnership along the biopharmaceutical value chain from early-stage R&D to market launch — including the integrated biotech solutions formed via the 2025 Biofidus merger.
• API Technology Transfer Structured transfer of API manufacturing or analytical processes from one site or team to another, ensuring GMP-compliant production continuity for pharmaceutical clients.
• FDF Technology Transfer Transfer of finished dosage form manufacturing processes between sites, supporting clients' commercial scale-up and multi-site manufacturing strategies.

Quantifiable outcome

• EcoVadis Gold Medal 2026 - Top 5% sustainability rating
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• BiofiduscoreStrategic or Co-development Partner · 25 March 2025Midas Pharma and Biofidus joined forces to create integrated biotech solutions. Biofidus specializes in contract development and manufacturing of biopharmaceutical products, complementing Midas Pharma's existing capabilities in the pharmaceutical value chain.
• Wuhu HuarencoreStrategic or Co-development Partner · 21 November 2024Strategic partnership for amidites supply. Wuhu Huaren is a manufacturer providing phosphoramidites used in oligonucleotide synthesis for mRNA-based medicines and diagnostics.
• HERMES PHARMAmajorStrategic or Co-development Partner · 25 September 2023New cooperation with HERMES PHARMA for pharmaceutical product development and manufacturing services, combining HERMES PHARMA's expertise in oral delivery with Midas Pharma's value chain capabilities.
• BASF ZoomLabminorStrategic or Co-development Partner · 23 February 2023Cooperation with BASF ZoomLab for pharmaceutical research and development support services.
• APONTIS PHARMAmajorStrategic or Co-development Partner · 14 December 2021Development partnership for pharmaceutical products. Multiple development partnerships established between Midas Pharma and APONTIS PHARMA for value-added medicines.
• GerresheimercoreStrategic or Co-development Partner · 9 November 2021Strategic partnership with Gerresheimer, a leading provider of drug delivery systems and pharmaceutical packaging solutions.
• AegirbiominorStrategic or Co-development Partner · 7 May 2021COVID-19 test distribution agreement with Aegirbio for rapid testing solutions.
• STADAmajorChannel Partner/ Reseller/ Distributor · 18 December 2020Strategic procurement partnership with STADA Arzneimittel AG for joint procurement initiatives and supply chain optimization.
• Fidelio Healthcare LimburgminorStrategic or Co-development Partner · 8 April 2020Non-exclusive cooperation agreement for pharmaceutical development and manufacturing services.
• CoripharmamajorOEM/ Whitelabel/ Licensing Partner · 3 February 2020Exclusive licensing partnership with Coripharma for pharmaceutical products. Extended in 2020 with a new cooperation agreement.

Scale indicators6 records

Recent moves11 records

Expansion highlights6 records

Direct peers

• Hovione: Portugal-based CDMO specializing in API development and manufacturing, particle engineering, and drug product services. Closely comparable to Midas's API/intermediates development and GMP manufacturing capabilities.
• Recipharm: European CDMO providing contract development and manufacturing of finished dosage forms and APIs to generic and branded pharma. Highly comparable to Midas in service scope and customer base across multiple dosage forms.
• Aenova Group: German-headquartered CDMO offering contract development and manufacturing of solid dosage forms, APIs, and soft gelatin capsules. Closest direct peer to Midas Pharma given geographic base and comparable FDF + API service mix.
• Alcami Corporation: US-based CDMO offering API development, finished dosage form manufacturing, and analytical services. Directly comparable mid-sized CDMO peer with similar service portfolio to Midas Pharma.
• Fareva: French-headquartered pharmaceutical CDMO with contract manufacturing of APIs, sterile injectables, and finished drug products. Direct comparable to Midas in European pharma services footprint, including France-based operations.
• Cambrex: US-headquartered CDMO specializing in API manufacturing, analytical services, and finished dosage forms. Comparable to Midas across the small-molecule API and FDF value chain, particularly for generic pharma customers.
• Haupt Pharma: German CDMO focused on contract development and manufacturing of sterile injectables and finished dosage forms. Comparable mid-sized European CDMO peer with similar product portfolio to Midas Pharma.

Broad incumbents

• Lonza Group: Swiss-headquartered global leader in CDMO services for both small molecules and biologics. Broad incumbent in the same industry as Midas but with materially larger scale and biologics dominance.

Regional players

• STADA Arzneimittel AG: German-headquartered generics and consumer healthcare company with strong EU footprint. Comparable as both a customer/partner (existing strategic procurement partnership with Midas) and a regional peer for finished dosage forms.

Emerging players

• Evotec: German-headquartered drug discovery and development services provider with growing CDMO capabilities through its Just-Evotec Biologics platform. Partially comparable to Midas's biopharma expansion via Biofidus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/midas-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Midas Pharma